13331-19-6

Basic information

• Product Name: 2-PROPYLBENZENE-1,3-DIOL
• Synonyms: 2-PROPYLBENZENE-1,3-DIOL;2-PROPYLRESORCINOL;2-PROPYLBENZENE-1,3-DIOL (2-PROPYLRESORCINOL);2-n-Propylresorcinol, 98%;1,3-Dihydroxy-2-propylbenzene;2-Propylresorcin;NSC 95252;2-Propyl-1,3-Dihydroxybenzene
• CAS NO: 13331-19-6
• Molecular Formula: C₉H₁₂O₂
• Molecular Weight: 152.19
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 13331-19-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 101-103°C
• Boiling Point: 280°C
• Flash Point: 135°C
• Appearance: /
• Density: 1.122
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.565
• PKA: 9.97±0.10(Predicted)
• Water Solubility: Solightly soluble in water.
• CAS DataBase Reference: 2-PROPYLBENZENE-1,3-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PROPYLBENZENE-1,3-DIOL(13331-19-6)
• EPA Substance Registry System: 2-PROPYLBENZENE-1,3-DIOL(13331-19-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 13331-19-6(Hazardous Substances Data)

Usage

Uses

2-Propylbenzene-1,3-diol is a useful building block used in the preparation of azolylbutoxychromenone derivatives as liver X receptor β-selective agonists.

InChI:InChI=1/C9H12O2/c1-2-4-7-8(10)5-3-6-9(7)11/h3,5-6,10-11H,2,4H2,1H3

Upstream product

• 172931-99-6 1,3-diethoxy-2-propylbenzene 
• 93114-94-4 3-methoxy-2-propylphenol 
• 150-19-6 O-methylresorcine 
• 90-33-5 7-hydroxy-4-methyl-chromen-2-one 
• 151-10-0 1,3-Dimethoxybenzene 
• 32774-65-5 2-n-propylcyclohexane-1,3-dione 
• 16929-64-9 1,3-Dimethoxy-2-(prop-1'-yl)benzene 
• 3361-72-6 1-(2,6-dihydroxyphenyl)-1-propanone 
• 93017-95-9 <3-Methoxy-2-propyl-phenyl>-4-brom-benzolsulfonat 
• 1746-89-0 2-allyl-1,3-dihydroxybenzene 
• 37592-19-1 3-allyloxyanisole 
• 3993-57-5 7-allyloxy-4-methyl-2H-chromen-2-one 
• 1616-54-2 8-allyl-7-hydroxy-4-methylcoumarin 

Downstream Products

• 95225-49-3 1,3-bis-(4-nitro-benzoyloxy)-2-propyl-benzene 
• 1242610-22-5 C₆₉H₉₂O₁₀ 
• 95903-40-5 methyl 2-(7-hydroxy-4-methyl-2-oxo-8-propyl-2Hchromen-3-yl)acetate 
• 1186116-57-3 5-(4-hydroxyphenyl)-5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione 
• 1186116-02-8 4-(4-methyl-2,5-dioxo-1-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidin-4-yl)benzoic acid 
• 1186116-03-9 5-(3,4-dimethoxyphenyl)-5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione 
• 1186116-08-4 5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)-butyl)-5-phenylimidazolidine-2,4-dione 
• 1186115-79-6 5-(4-methoxyphenyl)-5-methyl-3-(4-(2-oxo-8-n-propyl-4-(trifluoromethyl)-2H-chromen-7-yloxy)butyl)imidazolidine-2,4-dione 
• 152609-78-4 3-(2-cyanophenoxy)2-propylphenol 
• 152609-92-2 4-fluoro-2-(3-hydroxy-2-propyl-phenoxy)benzoic acid methyl ester 
• 84701-46-2 2,4-dihydroxy-3-propyl-benzaldehyde 
• 171880-18-5 2-(3-hydroxy-2-propylphenoxy)-phenylacetic acid methyl ester 
• 118684-12-1 2-tetrahydropyranyl 4-<<4-(trifluoroacetyl)-3-hydroxy-2-propylphenoxy>methyl>benzoate 
• 118683-21-9 4-{[4-(trifluoroacetyl)-3-hydroxy-2-propylphenoxy]methyl}benzoic acid 

Relevant articles and documents

Design and discovery of 2-oxochromene derivatives as liver X receptor β-selective agonists

In an attempt to molecularly design liver X receptor (LXR) β-selective agonists, we discovered that the combination of the 2-oxochromene moiety (head) and the imidazoline-2,4-dione moiety (tail) plays an important role in the expression potency and select

BENZYLIDENE RHODANINES

This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with . beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

Synthetic and structure/activity studies on acid-substituted 2- arylphenols: Discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist

Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These new analogues, the subject of a broad structure-activity investigation, displayed significantly increased in vitro and in vive activity as receptor antagonists of LTB4. A series of diaryl ether carboxylic acids demonstrated especially interesting activity and led to the discovery of compound 43b, 2- [2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]- propoxy]phenoxy]benzoic acid (LY293111), a 2-arylphenol-substituted diaryl ether carboxylic acid which displayed potent binding to human neutrophils (IC50 = 17 ± 4.6 nM) and guinea pig lung membranes (IC50 = 6.6 ± 0.71 nM), inhibition of LTB4-induced expression of the CD11b/CD18 receptor on human neutrophils (IC50 = 3.3 ± 0.81 nM), and inhibition of LTB4-induced contraction of guinea pig lung parenchyma (pK(B) = 8.7 ± 0.16). In vivo, 43b demonstrated potent activity in inhibiting LTB4-induced airway obstruction in the guinea pig when dosed by the oral (ED50 = 0.40 mg/kg) or intravenous (ED50 = 0.014 mg/kg) routes. A specific LTB4 receptor antagonist, 43b had little effect on inhibiting contractions of guinea pig lung parenchyma induced by leukotriene D4 (LTD4), histamine, carbachol, or U46619. Compound 43b has been chosen as a clinical candidate and is currently in phase I studies for a variety of inflammatory diseases.